Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Summary on Jun 27, 2018

June 27, 2018 - By Arturo Altman

During 2018 Q1 the big money sentiment decreased to 1.19. That’s change of 0.01, from 2017Q4’s 1.2. 18 investors sold all, 46 reduced holdings as Aerie Pharmaceuticals, Inc. ratio fall. 59 grew stakes while 17 funds acquired stakes. Funds hold 39.43 million shares thus 13.11% more from 2017Q4’s 34.86 million shares.
Jpmorgan Chase & Company reported 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Amalgamated Commercial Bank owns 4,535 shs for 0.01% of their capital. Parkside Bankshares holds 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 229 shs. 21,753 were reported by American Interest Group. Teacher Retirement Of Texas invested in 6,903 shs. Driehaus Capital Mngmt Limited Liability Co holds 16,539 shs or 0.03% of its capital. Healthcor Lp reported 1.20 million shs or 2.21% of all its holdings. Aperio Grp Limited Com accumulated 0% or 5,642 shs. State Common Retirement Fund reported 37,000 shs stake. First Personal Fincl invested 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Vident Invest Advisory Limited Liability Corporation has invested 0.02% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Qs Ltd accumulated 2,100 shs. Fmr reported 874,070 shs. Bamco New York accumulated 14,769 shs. Fred Alger reported 0.08% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Aerie Pharmaceuticals, Inc. registered $13.13 million net activity with 2 insider purchases and 4 sales since May 21, 2018. On Thursday, May 24 $135,806 worth of stock was sold by Kopczynski Casey C.. On Monday, May 21 the insider Cagle Gerald D. bought $50,245.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Total analysts of 6 have positions in Aerie Pharma (NASDAQ:AERI) as follows: 6 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 2, 2018 according to StockzIntelligence Inc Aerie Pharma has 10 analyst reports. On Thursday, March 1 the firm has “Buy” rating given by H.C. Wainwright. On Thursday, March 29 Mizuho maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Friday, February 16 the rating was reinitiated by H.C. Wainwright with “Buy”. On Tuesday, January 2 the stock has “Buy” rating by Stifel Nicolaus. On Wednesday, May 9 the firm has “Buy” rating by Mizuho given. In Tuesday, May 8 report Cantor Fitzgerald maintained the stock with “Buy” rating. In Wednesday, May 9 report H.C. Wainwright maintained the stock with “Buy” rating. On Wednesday, January 24 Canaccord Genuity maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. The company rating was maintained by Cantor Fitzgerald on Wednesday, February 28. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

The stock increased 0.66% or $0.45 during the last trading session, touching $68.5.Aerie Pharmaceuticals, Inc. has volume of 105,247 shares. Since June 27, 2017 AERI has declined 8.48% and is downtrending. The stock underperformed the S&P500 by 21.05%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.71 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

A couple more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were brought out by: Businesswire.com which released on June 18, 2018 “Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel”, also Gurufocus.com on June 09, 2018 brought out “Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Sold $9.3 million of Shares”, the next Businesswire.com is “Aerie Pharmaceuticals to Present at the NASDAQ 38” on June 02, 2018. Benzinga.com has article titled “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap”.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: